All patients underwent 18F-FDG PET/CT scan using either a Biograph 40 TruePoint PET/CT scanner (Siemens Healthcare, Erlangen, Germany) or Discovery STe PET/CT scanner (GE Healthcare, Waukesha, WI, USA). The patients fasted for at least 6 h, and glucose levels in the peripheral blood were confirmed to be lower than 140 mg/dL before 18F-FDG injection. Approximately 5.5 MBq of 18F-FDG per kilogram of body weight was administered intravenously 1 h before image acquisition. After the initial low-dose CT (Biograph 40 TruePoint, 36 mA, 120 kVp; Discovery STe, 30 mA, 130 kVp) without contrast-enhancement, standard PET imaging from the neck to the proximal thighs with an acquisition time of 2.5 min/bed position in 3-dimensional mode was performed. The PET images were reconstructed using ordered-subset expectation maximization (2 iterations, 20 subsets).
Discovery ste pet ct scanner
Manufactured by GE Healthcare
Sourced in United States, Germany
The Discovery STE PET/CT scanner is a medical imaging device that combines positron emission tomography (PET) and computed tomography (CT) technologies. It is designed to acquire high-quality images of the body's metabolic and anatomical information simultaneously.
Automatically generated - may contain errors
Lab products found in correlation
Discovery ls, by GE Healthcare (4 mentions)
Discovery 690, by GE Healthcare (3 mentions)
690 elite pet ct scanners, by GE Healthcare (3 mentions)
Biograph 16 pet ct scanner, by Siemens (3 mentions)
Biograph mct pet ct scanner, by Siemens (2 mentions)
Biograph 40 truepoint pet ct scanner, by Siemens (1 mentions)
Magnetom skyra, by Siemens (1 mentions)
Matlab 6, by MathWorks (1 mentions)
Gemini tf 64 scanner, by Philips (1 mentions)
Discovery mi pet ct scanner, by GE Healthcare (1 mentions)
Advantage workstation volume share 7, by GE Healthcare (1 mentions)
Biograph truepoint 40, by Siemens (1 mentions)
Gemini tf pet ct scanner, by Philips (1 mentions)
Discovery 690 pet ct scanner, by GE Healthcare (1 mentions)
Discovery pet ct 600 scanner, by GE Healthcare (1 mentions)
Biography mct pet ct scanner, by Siemens (1 mentions)
50 protocols using discovery ste pet ct scanner
1
18F-FDG PET/CT Imaging Protocol
2
Standardized [11C]-PiB-PET Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients underwent a standardized [11C]-PiB-PET scan at the Samsung or Asan Medical Center on a Discovery STE PET/CT scanner (GE Medical Systems, Milwaukee, WI, USA) to minimize any variance due to scanner differences. The detailed radiochemistry profiles, scanning protocol, and data analysis method were described in a previous study (8 (link)). Briefly, we calculated the PiB-uptake ratio of each voxel using the cerebellum as a reference region in the analysis. The global cortical PiB-uptake ratio was determined by combining the bilateral frontal, parietal, and temporal cortices, and the posterior cingulate gyrus. Patients were considered PiB-positive if their global PiB uptake ratio was more than 2 standard deviations (PiB retention ratio ≥ 1.5) from the mean of the normal controls.
3
FDG-PET Brain Imaging Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
FDG-PET brain scans were performed on the Discovery STE PET/CT scanner (GE Healthcare, Milwaukee, WI, USA) using standard techniques. Forty-seven horizontal slices were acquired with 3.27 and 3.75 mm transverse resolution and 1.95 and 0.488 mm resolution. All scans were performed as the participants rested with their eyes closed in a quiet, dimly lit room. The participants were required to fast for at least 4 hours. The measures of regional cerebral glucose metabolism were obtained following the administration of a 185–222 MBq intravenous injection (2-minute period) of FDG. The emission scans were obtained after a 45-minute uptake period. The images from 45–65 minutes post injection were used for the analysis. The whole brain glucose metabolism was obtained using standard filtering and reconstructing techniques.
4
Diagnostic accuracy of olfactory-stimulated fNIRS
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The previous study was designed as a prospective, patient-level, single-group, diagnostic accuracy study conducted in 97 elderly volunteers (aged > 60 years) suspected of having declining cognitive function between March 2, 2021, and August 30, 2021. Detailed methods have been described in a previous study [7 (link)]. Patients underwent open-label olfactory-stimulated fNIRS to measure oxygenation differences in the orbitofrontal cortex, 18F-florbetaben positron emission tomography (PET) amyloid imaging (Discovery STE PET-CT scanner, GE Medical Systems), three-dimensional brain imaging (MAGNETOM Skyra, Siemens Healthineers), apolipoprotein E (APOE) genotyping from peripheral blood samples, medical interviews (age, body mass index, sex, education, household income, smoking status, and Charlson comorbidity index [9 (link)]), Mini-Mental State Examination (MMSE), Korean Instrumental Activities of Daily Living (K-IADL) [10 (link)], and Seoul Neuropsychological Screening Battery (SNSB) [11 (link)].
5
FDG PET/CT Imaging of NSCLC Patients
6
Quantifying Brain Amyloid Burden with Florbetaben PET
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Brain PET images were acquired from participants 90–100 min after intravenous injection of a mean dose of 303 MBq 20% florbetaben, a fluorine-18-labeled stilbene derivative with the trade name of NeuraCeq [29 (link)], according to a standardized acquisition and imaging protocol in two hospitals. The florbetaben radiosynthesis, PET imaging scan, and data processing were performed as previously described in detail [30 (link), 31 ]. PET data were acquired with a Discovery STE PET-CT scanner (GE Medical Systems, Milwaukee, WI, USA).
The visual assessment of florbetaben PET images was performed in transaxial images using a gray scale by trained readers (J. Kim and H.-C. Song). Each brain region (frontal cortex, lateral temporal cortex, parietal cortex, and posterior cingulate cortex/precuneus) was visually assessed and scored according to the brain beta-amyloid plaque load (BAPL) scoring system for each PET scan. BAPL score: 1 = no beta-amyloid load, 2 = minor beta-amyloid load, 3 = significant beta-amyloid load. BAPL scores of 1 are classified as beta-amyloid-negative PET scan, and BAPL scores of 2 and 3 as beta-amyloid-positive PET scan [32 (link)].
The visual assessment of florbetaben PET images was performed in transaxial images using a gray scale by trained readers (J. Kim and H.-C. Song). Each brain region (frontal cortex, lateral temporal cortex, parietal cortex, and posterior cingulate cortex/precuneus) was visually assessed and scored according to the brain beta-amyloid plaque load (BAPL) scoring system for each PET scan. BAPL score: 1 = no beta-amyloid load, 2 = minor beta-amyloid load, 3 = significant beta-amyloid load. BAPL scores of 1 are classified as beta-amyloid-negative PET scan, and BAPL scores of 2 and 3 as beta-amyloid-positive PET scan [32 (link)].
7
PET Imaging of Amyloid Deposition
8
Quantitative Neuroimaging of Dopamine Receptors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
[18F]fallypride was synthesized in the radiochemistry laboratory consistent with the synthesis and quality control procedures outlined by US Food and Drug Administration INDs 47,245 and 120,035. Data were collected on a GE Discovery STE PET/CT scanner. Serial scan acquisition began simultaneously with a 5.0 mCi slow bolus injection of [18F]fallypride (specific activity >3000 Ci/mmol). CT scans were collected prior to each of the three emissions scans for the purpose of attenuation correction. Together, the scans lasted approximately 3.5 h with two breaks of 15–20 min (beginning approximately 70 min and 135 min after the beginning of the scan, respectively) included for patient comfort. During breaks, patients remained at rest but were permitted to stretch. Data for PD and HC subjects were acquired using identical MRI and PET technical parameters, with the single exception of a slightly different PET acquisition time protocol for the second and third dynamic runs, although total scan duration was similar (Supplementary Table 1; see Dang et al. (2017) (link); Dang et al. (2016) (link)). In past PET studies, differences in acquisition time protocol were not found to be a significant confound (Buckholtz et al., 2010 (link); Smith et al., 2016 (link)).
9
Alzheimer's Disease PiB PET Imaging Protocol
10
Multimodal PET Imaging for Tau and Amyloid
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
We performed static brain PET scans on all participants at 50–70 min after an intravenous injection of 185 MBq of [18F]THK-5351 for tau and 90–110 min after an intravenous injection of 300 MBq of [18F]florbetaben or 185 MBq of [18F]flutemetamol for amyloid. A Discovery 690, 710, or 690 Elite PET/CT scanner (GE Healthcare, Chicago, IL, USA) was used at Asan Medical Center, a Siemens Biograph 6 Truepoint (Siemens, Munich, Germany) was used at Gil Medical Center, and a Discovery STE PET/CT scanner (GE Healthcare, Chicago, IL, USA) was used at Samsung Medical Center. Three-dimensional Hoffman phantom PET image-based harmonization was conducted to identify the optimal size for the smoothing kernel to match the resolution of the digital gray matter (GM)/white matter (WM) segmentation with that of each PET scanner. Thereafter, we identified an optimal smoothing kernel that matched the spatial resolution of all scanners to that of the scanner with the lowest resolution; that is, the Discovery STE device (detailed methods are described at Joshi et al.26 (link)).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!